A 42-year-old woman from Delhi is found to have anti-HCV antibody positive on routine screening. She is asymptomatic with normal liver enzymes (ALT 28 U/L, AST 32 U/L) and normal bilirubin. HCV RNA (RT-PCR) is positive. Abdominal ultrasound shows no features of cirrhosis. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient has **confirmed chronic hepatitis C** (anti-HCV positive, HCV RNA positive by RT-PCR). The next step is to assess disease severity and genotype before initiating direct-acting antiviral (DAA) therapy. ## Why Genotyping and Fibrosis Assessment Are Mandatory **Key Point:** HCV genotyping determines the duration and choice of DAA regimen. Fibrosis staging is essential to identify cirrhosis, which alters treatment duration and requires hepatocellular carcinoma (HCC) surveillance. **High-Yield:** Current WHO and Indian guidelines (AASLD/IDSA 2023) recommend: 1. **HCV genotyping** (genotypes 1–6; genotype 3 requires longer treatment in some regimens) 2. **Fibrosis assessment** via transient elastography (TE) or liver biopsy to stage disease (F0–F4) 3. **DAA selection** based on genotype and fibrosis stage ### Fibrosis Assessment Methods | Method | Cutoff for Cirrhosis (F4) | Advantages | Limitations | |--------|---------------------------|-----------|-------------| | **Transient Elastography (TE)** | >14.6 kPa | Non-invasive, reproducible, rapid | Obesity, ascites may reduce accuracy | | **Liver Biopsy** | Histologic staging | Gold standard, can assess inflammation | Invasive, sampling error, patient discomfort | | **FIB-4 Index** | >2.67 | Non-invasive, uses routine labs | Less accurate than TE | | **APRI Score** | >2 | Non-invasive, uses AST/platelets | Less accurate than TE | **Clinical Pearl:** In this patient with normal ALT and no ultrasound evidence of cirrhosis, transient elastography is the preferred first-line fibrosis assessment (non-invasive, rapid, cost-effective). ### Treatment Algorithm ```mermaid flowchart TD A[Anti-HCV positive + HCV RNA positive]:::outcome --> B[Perform HCV genotyping]:::action B --> C[Assess fibrosis with TE or biopsy]:::action C --> D{Cirrhosis present?}:::decision D -->|No cirrhosis| E[Genotype 1/2/4/5/6: SOF/VEL 12 weeks]:::action D -->|No cirrhosis| F[Genotype 3: SOF/VEL/VOX 12 weeks]:::action D -->|Cirrhosis| G[Extend treatment to 12-24 weeks depending on genotype]:::action D -->|Cirrhosis| H[Screen for HCC before and during treatment]:::action E --> I[Initiate DAA therapy]:::action F --> I G --> I H --> I ``` ## Why Immediate DAA Therapy Without Genotyping Is Wrong **Warning:** Starting DAA without genotyping risks: - Suboptimal regimen selection (some genotypes require longer durations or different agents) - Reduced cure rates if the chosen regimen is not optimal for that genotype - Unnecessary cost if a shorter, cheaper regimen is available ## Why Deferring Treatment Until ALT Elevation Is Wrong **High-Yield:** Modern guidelines recommend **treat-all** strategy for chronic HCV, regardless of ALT level or fibrosis stage. Delaying treatment: - Allows continued viral replication and fibrosis progression - Increases risk of cirrhosis, HCC, and decompensation - Is not supported by current evidence (DAAs are highly effective and safe) **Mnemonic — HCV Genotyping Impact:** **GENO-DURATION** (Genotype determines duration: Gen 1/2/4/5/6 = 12 weeks; Gen 3 = 12 weeks with velpatasvir/sofosbuvir/voxilaprevir).